Compare · MLTX vs NVO
MLTX vs NVO
Side-by-side comparison of MoonLake Immunotherapeutics (MLTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MLTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 139.4x MLTX ($1.34B).
- Over the past year, MLTX is down 64.3% and NVO is down 41.7% - NVO leads by 22.6 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 6 for MLTX).
- Both have 25 recent analyst ratings on file.
- Company
- MoonLake Immunotherapeutics
- Novo Nordisk A/S
- Price
- $18.25+2.10%
- $42.01-2.10%
- Market cap
- $1.34B
- $187.53B
- 1M return
- +4.02%
- -5.38%
- 1Y return
- -64.27%
- -41.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 6
- 11
- Recent ratings
- 25
- 25
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MLTX
- MoonLake Immunotherapeutics filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Amendment: SEC Form SCHEDULE 13G/A filed by MoonLake Immunotherapeutics
- Chief Financial Officer Bodenstedt Matthias sold $273,333 worth of Class A ordinary shares (13,653 units at $20.02) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,172,431 units (SEC Form 4)
- SEC Form 10-Q filed by MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
- SEC Form DEFA14A filed by MoonLake Immunotherapeutics
- SEC Form DEF 14A filed by MoonLake Immunotherapeutics
- SEC Form 4 filed by Bodenstedt Matthias
- SEC Form 4 filed by Santos Da Silva Jorge
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates